{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:03:30Z","timestamp":1788973410953,"version":"build-2803163510"},"reference-count":19,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection (CDI) causes a significant national health care burden. Literature has demonstrated lower rates of CDI recurrence with fidaxomicin compared with oral vancomycin. However, patients are sometimes switched to oral vancomycin before completing a fidaxomicin course.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study is to evaluate rates of CDI recurrence in full courses of fidaxomicin versus partial courses of fidaxomicin followed by a switch to oral vancomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this single-center, retrospective, cohort study of adults with CDI, patients were screened for inclusion if they received either a full 10-day course of fidaxomicin or partial course of fidaxomicin followed by a switch to oral vancomycin. The primary outcome was the rate of CDI recurrence within 30 days after completion of initial therapy determined by a positive CDI test and initiation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ninety-nine patients received a full course of fidaxomicin, and 95 patients received a partial course of fidaxomicin followed by oral vancomycin. Mean age was lower in the full course group compared with the partial course (65.3 years vs 71.5 years,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.002).\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection recurrence occurred in 5.1% of the full course group and 7.4% of the partial therapy group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.503) at 30 days and 13.1% versus 14.7% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.747) at 90 days.\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection\u2013related readmissions at 30 days were similar in the full course and partial course groups (7.1% vs 4.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.389).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Partial courses of fidaxomicin followed by oral vancomycin had similar 30-day CDI recurrence compared with full course fidaxomicin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251332946","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:32:22Z","timestamp":1746502342000},"page":"1094-1100","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Partial Courses of Fidaxomicin Followed by Oral Vancomycin and the Effect on Recurrence of\n                    <i>Clostridioides difficile<\/i>\n                    Infections"],"prefix":"10.1177","volume":"59","author":[{"given":"Irene-Constantina","family":"Papamanolis","sequence":"first","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"},{"name":"University Hospital, Newark, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Stornelli","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-8453","authenticated-orcid":false,"given":"Nathan","family":"Everson","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"},{"name":"Henry Ford Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"},{"name":"Children\u2019s Healthcare of Atlanta, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Kamrada","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen Rachel","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-8552","authenticated-orcid":false,"given":"Lauren","family":"McDaniel","sequence":"additional","affiliation":[{"name":"Carilion Roanoke Memorial Hospital, Carilion Clinic, Roanoke, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910215"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2008.08.012"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00480-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18071"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab549"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.038"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.09.013"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis440"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2778"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.11.004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.08.008"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac138"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00665-1"},{"key":"e_1_3_2_16_2","unstructured":"National Healthcare Safety Network. Multidrug-resistant organism & Clostridioides difficile infection (MDRO\/CDI) module. MDRO & CDI Protocol. Accessed January 2025. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/12pscmdro_cdadcurrent.pdf"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1857"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy149"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae119"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis338"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251332946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251332946","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251332946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:06Z","timestamp":1777374846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251332946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/10600280251332946"],"URL":"https:\/\/doi.org\/10.1177\/10600280251332946","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}